suppressors and further cause the tumorigenicity in human. As reported, differentially expressed miRNAs have contributed a lot in diverse kinds of cancers. [6] [7] [8] Mechanism about the interactions between aberrantly expressed miRNAs and their targets mRNAs in cancer is under urgent priority to be revealed.
MiR-1258 which located on chromosome 2q31.3 was first shown to inhibit breast cancer brain metastasis by targeting heparanase. 9 Later, other studies demonstrated miR-1258 can function in nonsmall-cell lung cancer, liver cancer and gastric cancer [10] [11] [12] ; however, the researches about miR-1258 in the field of CRC are still blank.
In the present study, we tried to elucidate the roles of miR-1258 in CRC. We discovered that miR-1258 is downregulated in CRC, after experiments both in vivo and vitro, we found overexpressed miR-1258 can inhibit the proliferation and cause cell-cycle arrest at G0/ G1 in CRC.
Through bioinformatic prediction and experimental confirmation, we identified E2F transcription factor 8 (E2F8) as the putative direct target of miR-1258. E2F8 is a family of transcription factors which regulate the expression of genes required for progression through the cell cycle. 13 Former studies focused on E2F8
and revealed lots of valuable findings, and Sun et al discovered that E2F8 promotes papillary thyroid cancer progression via regulating cell cycle. 14 Deng et al found that E2F8 may constitute a potential therapeutic target hepatocellular carcinoma. 15 However, mechanism of E2F8 in CRC has not been clarified. In our study, we indicated E2F8, which can be controlled by miR-1258 directly, was upregulated in CRC tissues and CRC cell lines and can abolish the effects caused by miR-1258 in inhibiting cell proliferation and regulating cell cycle.
In conclusion, we investigated the functions of miR-1258 and its correlations with E2F8 in CRC. Our findings demonstrated that miR-1258 downregulation has vital effects in regulating cell cycle and inhibiting proliferation of CRC, providing miR-1258 the role as a potential novel therapeutic target in CRC.
| MATERIAL S AND ME THODS

| Tissues specimens
We obtained 60 paired tumour and adjacent normal tissues 
| CRC cell lines and cell culture
CRC cell lines including LoVo, HCT116, SW480, DLD-1, HT29 and normal epithelial colon cell NCM460 were purchased from American Type Culture Collection (ATCC, USA). The culture condition follows Dulbecco's modified Eagle's medium (DMEM; Winsent, Canada) supplemented with 10% foetal bovine serum (Wisent, Canada), 100 U/ mL penicillin and 100 μg/mL streptomycin in a moist incubator (stabilize at 5% CO 2 and 37°C).
| Vector construction, lentivirus production and cell transfections
LV2-hsa-miR-1258-mimic vector (miR-1258-mimics) and the LV2-hsa-miR-1258-inhibitor vector (miR-1258-inhibitor) were constructed by lentiviral vectors (GenePharma, Shanghai, China). We also constructed a negative control with LV2 empty lentiviral. We infected DLD-1 and HCT116 grown to 40%-50% confluence by using lentiviral vectors at an appropriate multiplicity of infection (MOI).
Stable transfected cells were screened by puromycin according to protocols. CRC cell lines were transfected with the E2F8 overexpressing recombinant vector pcDNA3.1-E2F8 (GenePharma, China)
to overexpress E2F8 and empty plasmid as negative control (NC).
The primer to overexpress E2F8 were designed as follows: 5′-CGG GATCCGAGGAATTTACAGAATGGAGAAC-3′ (forward); 5′-CCCG CTCTAGATTAATGGACATCCTCTGTTGAGACTTC-3′ (reverse). To knockdown E2F8, small interfering RNAs (siRNA) targeting the encoding region of E2F8 was purchased from GenePharma (Shanghai, China), and we used siRNA transfection reagent (Invitrogen) according to the protocols. Nontargeting control siRNA was used as negative control. The sequences used were siRNA for E2F8: 5′-GGCCA AAGACUGUAUACACTT-3′(sense), 5′-GUGUAUACAGUCUUUGGC CTT-3′(antisense); nontargeting control siRNA (NC): 5′-UUCUCCG AACGUGUCACGUTT-3′(sense), 5′-ACGUGACACGUUCGGAGAATT -3′(antisense).
| Quantitative real-time PCR (qRT-PCR) and miRNA RT-PCR
Following the manufacturer's instructions, total RNA was extracted from CRC tissues and cells with TRIzol reagent (Invitrogen, USA). For qRT-PCR of mRNA, total RNA was further reverse transcribed into cDNA through PrimeScript RT reagent kit (Takara, Dalian, China).
For miRNA RT-PCR, we used Hairpin-it ™ miRNA qPCR Quantitation Kit (GenePharma, China) to perform Target-specific reverse transcription and the TaqMan microRNA assay. The reactions were processed using a 7500 Realtime PCR System (Applied Biosystems, Carlsbad, CA, USA) with SYBR Premix Ex Taq Kit (TaKaRa). The specific primers of target mRNA/miRNA and internal control were designed as following: E2F8 forward, 5′-CCAACCCTGCTGTGAATA-3′
and E2F8 reverse 5′-TTTCTGGCTCATTACCCT-3′; β-actin forward, 5′-GCATCGTCACCAACTGGGAC-3′ and β-actin reverse, 5′-AC CTGGCCGTCAGGCAGCTC-3′, hsa-miR-1258 forward, 5′-AGTTAGG ATTAGGTCGTGGAA-3′; Universal, 5′-GCGAGCA CAGAATTAAT ACGAC-3′; U6 forward, 5′-CTCGCTTC GGCAGCACA-3′ and U6 reverse, 5′-AACGCTTCACGAATTTGCGT-3′. Expression level was normalized to internal controls (β-actin or U6) and results were shown in form of relative expression calculated by 2 −ΔΔCT method.
| Immunohistochemistry
All specimens were fixed in 4% formalin and then embedded in par- 
| Cell proliferation assay
We used Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan) to detect the cell proliferation according to the manufacturer's instructions; 2000 cells/well were seeded into 96-well plates and cultured as previously described; 10 uL CCK-8 solution mixed with serumfree medium were added every 24 hours. After 2-hour incubation, we used a microplate reader to detect the absorbency at a test wavelength of 450 nm and a reference wavelength of 630 nm.
| Colony formation assay
Under the culture condition described before, we seeded 500 cells/ well in 6-well plate. After a week, each well was processed the following procedure: washed with phosphate buffer saline (PBS) for three times in room temperature, then fixed by ethyl alcohol for 30 seconds and finally stained with crystal violet. Colonies were counted by naked eye after rinsed by PBS.
| 5-Ethynyl-2′-deoxyuridine (EdU) assay
We measured cell proliferation using the EdU assay kit (RiboBio, China). Cells were seeded into 24-well plates (2 × 10 4 cells/well) and cultured with DMEM (10% FBS) for 24 hours before the addition of EdU (50 μmol/L). According to the protocols, cells were then incubated for 2 hours at 37°C, fixed in 4% formaldehyde for 30 minutes and permeabilized with 0.5% TritonX-100 for 10 minutes at room temperature. After washing with PBS, 1× ApolloR reaction cocktail (400 μL) was added to react with the EdU for 30 minutes.
Subsequently, Hoechest33342 (400 μL) was added for 30 minutes to visualize the nuclei. Images of cells were obtained under a Nikon microscope (Nikon, Japan). Proliferation was analysed using the mean number cells in three fields for each sample.
| Cell-cycle analysis
Transfected cells were firstly digested by trypsin and then centri- 
| Western blot
According to the manufacturer's instructions, we used a RIPA kit E2F8 (Abcam, 1:1000), CCND1, p21, p27, CDK2 and β-actin were used as an internal control.
| Luciferase report assay
Sequences corresponding to the 3′-UTR of E2F8 mRNA and containing the wild-type or mutated miR-1258 binding sequence were synthesized by GeneScript (Nanjing, China). We inserted these sequences into the XbaI and SacI site of pmirGLO dual-luciferase miRNA target expression vector (Promega, USA). They were cotransfected with vectors and miR-1258-mimics/miR-1258-inhibitor or miR-NC by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Luciferase activity was measured by Luciferase Reporter Assay System (Promega, USA).
| RNA immunoprecipitation assay
The Magna RIP RNA-Binding Protein Immunoprecipitation Kit 
| Tumour xenograft in nude mouse model
This study was approved by Animal Ethics Committee of Nanjing Medical University (NJMU). Male BALB/c nude mice (aged 4 weeks)
were purchased from the Animal Center of NJMU. 2 × 10 6 transfected cells were injected bilaterally and subcutaneously into the flanks of the nude mice. Tumours were measured by Vernier callipers every 5 days, and the mice were euthanized after 3 weeks.
The formula used to calculate the tumour volume follows: volume = (width 2 × length)/2.
| Statistical analysis
All experiments in this research were performed in triplicate independently. All analysis was performed using spss 19.0 software.
Chi-squared test was used to detect differences in the data of clinicopathological findings. Pearson correlation was used to analyse correlation of expression between miR-1258 and E2F8. The data were shown as mean ± standard deviation (SD). Student's unpaired t test was used to determine the significant differences of other results. The data were considered statistically significant; "*" indicates "P < 0.05," "**"indicates "P < 0.01," and "***" indicates "P < 0.001."
| RE SULTS
| miR-1258 is downregulated in CRC tissues and CRC cell lines
In order to investigate the expression level of miR-1258 in CRC, we obtained 60 paired CRC tissues and adjacent normal tissues. By miRNA RT-PCR, we identified miR-1258 is downregulated in CRC tissues compared with adjacent normal tissues ( Figure 1A ). We also detected the expression of miR-1258 in CRC cell lines (LoVo, HCT116, SW480, DLD-1, HT29) as well as normal epithelial colon cell NCM460. As shown in Figure 1B, Low expression groups to analyse the correlation between miR-1258 and proliferation. Figure 1C indicated that higher expression of miR-1258 owns a lower proliferation index.
| MiR-1258 inhibits the proliferation and arrests cell cycle at G0/G1 phase
We selected two CRC cell lines according to their expression pattern, HCT116 and DLD-1, which owned lowest and highest expression level of miR-1258 among these five CRC cell lines, demonstrating Figure 2A , relative expression of miR-1258 in HCT116-micmcis and DLD-1-inhibitor was significant higher and lower, respectively, than the control group.
We carried out CCK-8, colony formation and EdU assay to evaluate the influence of miR-1258 in proliferation. As shown in Figure 2B , results of CCK-8 showed that upregulated miR-1258 inhibited the proliferation of HCT116 while downregulated miR-1258 tends out the opposite effects in DLD-1. As the same, upregulated miR-1258 decreased the ability of colony formation in HCT116; in contrast, downregulated miR-1258 promoted the colony formation in DLD-1 ( Figure 2C ). Results of EdU were shown in Figure 2D , the number of HCT116 cells incorporating EdU in the miR-1258-mimics-treated group was distinctly decreased compared with the number in the control group, while DLD-1 cells transfected with the miR-1258-inhibitor revealed a significant increase in cell proliferation compared with that of the control group. We used flow cytometry to analyse the effects of dysregulated miR-1258 in cell cycle, results
were shown in Figure 2E , overexpressed miR-1258 in HCT116 presented a significant increase in the percentage of cells in the G0/ G1 phase while downregulated miR-1258 in DLD-1 indicated cell cycle was arrest in S phase. These findings demonstrated that overexpressed miR-1258 inhibited CRC cell proliferation and induced cell-cycle arrest in G0/G1 phase.
| MiR-1258 suppresses E2F8 expression via interacting directly with a hypothetic binding site of E2F8-3′-UTR
To predict the potential target of miR-1258, we used bioinformatics tools in public database including TargetScan and mirTarBase. A putative binding site of E2F8-3′-UTR for miR-1258 was identified.
We further utilized dual luciferase reporter assays to verify our prediction. Mutant-type (MUT) and wild-type (WT) E2F8-3′-UTR sequences (the former containing site-directed mutations in the putative miR-1258 target sites) were cloned into reporter plasmids.
Luciferase activity significantly decreased in HCT116 and DLD-1 cells co-transfected with miR-1258-mimics and the pmirGLO-WT-E2F8-3′-UTR. In contrast, luciferase activity increased in HCT116
and DLD-1 cells co-transfected with miR-1258-inhibitor and the pmirGLO-WT-E2F8-3′-UTR. However, no significant reduction was observed about luciferase activity in group co-transfected with pmirGLO-MUT-E2F8-3′-UTR and miR-1258-mimics/miR-1258-inhibitor ( Figure 3A) . We further performed RIP to explore the binding status between E2F8 and miR-1258 in CRC cell lines.
Results showed that miR-1258 and E2F8 were both enriched in Ago2-coating beads relative to IgG control group. In HCT116 and DLD-1 transfected with miR-1258-mimics, we identified E2F8 is upregulated compared with miR-NC treated group through RIP assay. The reverse changes of E2F8 were also observed in HCT116
and DLD-1 transfected with miR-1258-inhibitor ( Figure 3B ).
Expression of E2F8 and its correlation with miR-1258 were also detected. In 60 paired CRC tissues and adjacent normal tissues, expression level of E2F8 was upregulated in CRC tissues compared with adjacent normal tissues and negatively associated with miR-1258 according to qRT-PCR ( Figure 4A ). We used western blot and IHC to detect expression of E2F8 in 6 paired CRC tissues and adjacent normal tissues ( Figure 4B ). We also research the was associated with bigger tumour size ( Table 1 ). In CRC cell lines, E2F8 was upregulated in CRC cell lines compared with NCM460
(normal epithelial colon cell) ( Figure 4C ). In transfected CRC cells, we discovered that expression level of E2F8 is lower in HCT116-miR-1258-mimics and higher in DLD-1-miR-1258-inhibitor compared with the negative control in tools of qRT-PCR and western blot ( Figure 4D ). These findings demonstrated that miR-1258 can directly negatively control E2F8.
| MiR-1258 inhibits proliferation and regulates cell cycle by targeting E2F8
To further investigate the influence of interaction between miR-1258 and E2F8 in CRC, we conducted the rescue experiments. In our rescue experiments, we designed two comparisons, the first Figure 5B ). Subsequently, the colony formation assay, EdU assay and CCK-8 assay were applied. As shown in Figure 5C -E, upregulated E2F8 abolished the effect of upregulated miR-1258 in suppressing HCT116 proliferation.
Similarly, effect of promoting DLD-1 proliferation made by downregulated miR-1258 can be counteracted by downregulated E2F8.
We also used flow cytometric to explore whether the effects of miR-1258 on cell cycle were mediated by the regulation of E2F8.
It turned out that upregulated E2F8 can abolish cell-cycle arrest caused by upregulated miR-1258 in HCT116 cells. Likewise, downregulated E2F8 can cause cell-cycle arrest in the G0/G1 phase in downregulated miR-1258 DLD-1 cells ( Figure 5F ). These findings suggested that miR-1258 inhibits proliferation and regulates cell cycle by directly targeting E2F8.
F I G U R E 4 Expression pattern of E2F8 in CRC.
A, Expression of E2F8 was upregulated in 60 paired CRC tissues compared with adjacent normal tissues and was negatively correlated with miR-1258. B, Immunohistochemistry showed the expression level of miR-1258 in CRC tissues and paired adjacent normal tissues, western blot showed the expression level of miR-1258 in 6 paired CRC tissues and adjacent normal tissues. C, Expression of E2F8 in CRC cell lines and normal epithelial colon cell NCM460 were detected by qRT-PCR and western blot. D, Expression of E2F8 in CRC cell lines transfected with relevant lentivirus was detected by qRT-PCR and western blot. (*P < 0.05, **P < 0.01, ***P < 0.001)
| MiR-1258 influences CCND1/p21 through E2F8
Previous studies have revealed that E2F8 can influence the cell cycle by interacting with some key factors. 14, 15 In our study, as described before, miR-1258 can function by directly targeting E2F8,
we wonder whether miR-1258 could influence any key factors in cell cycle in CRC, we detected the expression of some key factors in cell cycle by qRT-PCR and western blot, including CCND1, p27, p21 and CDK2. As shown in Figure 6A , B, in HCT116-miR-1258-mimics group, E2F8 and CCND1 were decreased while p21 was increased, and no significant changes were observed in p27 and CDK2 compared with the control group. In contrast, the opposite results were discovered in DLD-1-miR-1258-inhibitor group. We further used rescue experiments to find if the effects on influencing CCND1/p21 caused by miR-1258 can be partially counteracted by E2F8, and the results confirmed our hypothesis ( Figure 6C , D). Taken together, we determined that miR-1258 can regulate CCND1/p21 through regulating E2F8.
| MiR-1258 inhibits tumorigenicity in vivo
To reveal the effects of miR-1258 on tumorigenicity in vivo, HCT116 and DLD-1 cells transfected with vectors above were injected into the flanks of nude mice to generate tumours ectopically.
As shown in Figure 7A , in HCT116 group, cells transfected with miR-1258-mimics generated smaller and lighter tumours, while it showed the inverse results in DLD-1 group. We used miRNA RT-PCR to confirm the expression of miR-1258 in mice tumour tissues, HCT116 group transfected with miR-1258-mimics owned a higher expression level, while DLD-1 group transfected with miR-1258-inhibitor showed a lower expression ( Figure 7B ). We used qRT-PCR, western blot and immunohistochemical to detect the expression of E2F8 in mice tumours, E2F8 was downregulated in HCT116 group transfected with miR-1258-mimics and upregulated in DLD-1 group transfected with miR-1258-inhibitor ( Figure 7C , D). We also stained mice tumours with Ki-67, and results indicated that HCT116 group transfected with miR-1258-mimics showed a lower proliferation index and DLD-1 group presented the inverse trend ( Figure 7E ). These findings demonstrated that miR-1258 can inhibit the tumorigenicity in vivo.
| D ISCUSS I ON
CRC has a high incidence and mortality rate worldwide; however, we 20 These findings all proved that miRNAs have critical effects in tumorigenicity and its urgent for us to reveal the mechanism of miRNA in process of CRC.
MiR-1258 was identified as a tumour suppressor in multicancers, including breast cancer, liver cancer, non-small-cell lung cancer and gastric cancer [9] [10] [11] [12] ; however, the expression pattern and its role in These findings demonstrated that upregulated miR-1258 can serve as a tumour suppressor in the process of CRC.
To further research the mechanism of miR-1258 in CRC, we used bioinformatics tools to predict the putative targets of miR-1258. Among these candidate target mRNAs, we chose to investigate E2F8. E2F8 which located on chromosome 11p15 encodes a member of a family of transcription factors which regulate the genes required for developments through the cell cycle. E2F8 can regulate progression from G1 to S phase by ensuring the nucleus divides at the proper time. 13 E2F8 was widely researched, and previous studies identified its crucial role in many biological processes. Among these biological processes, E2F8 functions most significantly in regulating cell cycle compared with other biological processes. 13 Moreover, E2F8 was also widely researched in different kinds of cancers, and its mechanism was often defined as oncogene by influencing the cell cycle. Jin et al discovered that by suppressing E2F8, metformin can induce cell-cycle arrest at G1 phase in lung cancer cells. 21 Sun et al found E2F8 can promote the papillary thyroid cancer progression via regulating cell cycle. 14 Ye F I G U R E 5 MiR-1258 inhibits proliferation and regulates cell cycle by targeting E2F8. A, Expression of E2F8 was verified in transfected CRC cell lines by qRT-PCR and western blot. B, Expression of E2F8 was confirmed by qRT-PCR and western blot in co-transfected CRC cell lines. (C, D, E) CCK-8, colony formation and EdU showed the situations of proliferation in co-transfected and transfected CRC cell lines. F, Changes of cell cycle in co-transfected CRC cell lines. (*P < 0.05, **P < 0.01, ***P < 0.001) et al indicated that upregulated E2F8 modulate G1/S phase transition and further promote the cell proliferation in breast cancer. 22 However, the researches about E2F8 in CRC remain rare and its mechanism needs to be clarified. In our study, we identified differential expression of E2F8 between CRC tissues and adjacent normal tissues. Expression pattern of E2F8 in CRC cell lines compared to epithelial colon cell NCM460 was consistent with that in tissues.
E2F8 expression was also found to be associated with tumour size exceeding 3 cm in CRC patients. We further used luciferase reporter assays and RIP assays to confirm that miR-1258 negatively regulated E2F8 at the translational level by binding to a specific target site within the 3′-UTR. Upregulated miR-1258 in CRC cell lines can degrade E2F8 mRNA and ectopic expression of E2F8 significantly abolished the effects of the suppression of proliferation and cell-cycle arrest in G0/G1 phase caused by upregulated miR-1258. Similarly, transfection of si-E2F8 reversed the promotion of proliferation and cell-cycle arrest in S phase caused by miR-1258 downregulation. In summary, miR-1258 affects the tumorigenicity by directly targeting E2F8 and E2F8 can abolish the effects that miR-1258 caused.
Sustaining proliferation is considered to be a remarkable sign of cancer. 23 Generally, cell cycle is dysregulated in cancer cells, thereby breaking homeostasis of cell number and causing uncontrolled cell proliferation. 24 As former studies described, E2F8 can be a factor in regulating cell cycle; in our study, we revealed that dysregulated miR-1258 can play its role by directly targeting E2F8. By western blot, we
found that miR-1258 can influence the p21 which can be a universal inhibitor of cyclin kinases 25 and CCND1 which was identified as a key factor in regulating cell cycle. 26 In miR-1258-mimics group, we detected downregulated E2F8, CCND1 and upregulated p21, and the reverse results were also observed in miR-1258-inhibitor group.
Through rescue experiments, we found that E2F8 can partially reverse the expression changes of CCND1 and p21 caused by dysregulated miR-1258, indicating that miR-1258 may regulate cell cycle via CCND1/p21 through negatively controlling E2F8. However, the detailed mechanism of miR-1258 in regulating cell cycle still needs further investigation.
In conclusion, our study indicated that miR-1258 can suppress the progression and developments of CRC through influencing cell cycle by targeting E2F8 directly and provided miR-1258 the role as a novel therapeutic target for CRC.
| CON CLUS IONS
Taken together, miR-1258 was downregulated in CRC and E2F8 was upregulated. Upregulated miR-1258 can inhibit cell proliferation and regulate cell cycle by directly negatively controlling E2F8, providing a novel insight of miR-1258 as a therapeutic target for human CRC.
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